Skip to main content

Table 2 Risks and risk differences of 30-day mortality categorized by marker positivity for soluble tumor necrosis factor receptor-1 (sTNFR1), interleukin-8 (IL8), and angiopoietin-2 (Ang2), in the derivation (N = 200) and validation (N = 200) cohorts. Standardized risks and risk differences are reported for the derivation cohort, adjusted for age, cirrhosis, immunocompromised state, septic shock at presentation, and mechanical ventilation at presentation. Crude risks and risk differences are reported for the validation cohort. The IL8 analysis is limited to immunocompetent patients (N = 105 in derivation cohort, N = 173 in validation cohort)

From: Plasma sTNFR1 and IL8 for prognostic enrichment in sepsis trials: a prospective cohort study

Marker and siteNumber (%) of subjects above threshold30-day mortality (95% CI) if below threshold30-day mortality (95% CI) if above thresholdRisk difference of 30-day mortality (95% CI) if above thresholdp
sTNFR1 > 8861 pg/ml
 Derivation93 (46.5%)30.4% (21.6, 39.2)52.0% (42.3, 61.7)21.6% (8.1, 35.2)0.002
 Validation67 (33.5%)21.1% (14.1, 28.0)38.8% (27.1, 50.5)17.8% (4.2, 31.3)0.010
IL8 > 94 pg/ml
 Derivation57 (54.3%)23.2% (11.8, 34.6)40.9% (29.8, 52.0)17.7% (1.6, 33.8)0.031
 Validation68 (39.3%)18.9% (11.9, 25.8)44.1% (32.3, 55.9)27.0% (13.2, 40.8)< 0.001
Ang2 > 9761 pg/ml
 Derivation139 (69.5%)25.8% (14.6, 37.1)47.1% (39.3, 54.9)21.3% (7.3, 35.3)0.003
 Validation127 (63.5%)19.2% (10.2, 28.2)31.5% (23.4, 39.6)12.3% (0.2, 24.4)0.046